Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/27162
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nacul, L | - |
dc.contributor.author | O'Boyle, S | - |
dc.contributor.author | Palla, L | - |
dc.contributor.author | Nacul, FE | - |
dc.contributor.author | Mudie, K | - |
dc.contributor.author | Kingdon, CC | - |
dc.contributor.author | Cliff, JM | - |
dc.contributor.author | Clark, TG | - |
dc.contributor.author | Dockrell, HM | - |
dc.contributor.author | Lacerda, EM | - |
dc.date.accessioned | 2023-09-12T09:37:18Z | - |
dc.date.available | 2023-09-12T09:37:18Z | - |
dc.date.issued | 2020-08-11 | - |
dc.identifier | ORCID iD: Jacqueline M. Cliff https://orcid.org/0000-0002-5653-1818 | - |
dc.identifier | 826 | - |
dc.identifier.citation | Nacul, L. et al. (2020) 'How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS', Frontiers in Neurology, 11, 826, pp. 1 - 13. doi: 10.3389/fneur.2020.00826. | en_US |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/27162 | - |
dc.description | Data Availability Statement: The datasets generated for this study are available on request to the corresponding author. | en_US |
dc.description.abstract | Copyright .© 2020 Nacul, O'Boyle, Palla, Nacul, Mudie, Kingdon, Cliff, Clark, Dockrell and Lacerda. We propose a framework for understanding and interpreting the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) that considers wider determinants of health and long-term temporal variation in pathophysiological features and disease phenotype throughout the natural history of the disease. As in other chronic diseases, ME/CFS evolves through different stages, from asymptomatic predisposition, progressing to a prodromal stage, and then to symptomatic disease. Disease incidence depends on genetic makeup and environment factors, the exposure to singular or repeated insults, and the nature of the host response. In people who develop ME/CFS, normal homeostatic processes in response to adverse insults may be replaced by aberrant responses leading to dysfunctional states. Thus, the predominantly neuro-immune manifestations, underlined by a hyper-metabolic state, that characterize early disease, may be followed by various processes leading to multi-systemic abnormalities and related symptoms. This abnormal state and the effects of a range of mediators such as products of oxidative and nitrosamine stress, may lead to progressive cell and metabolic dysfunction culminating in a hypometabolic state with low energy production. These processes do not seem to happen uniformly; although a spiraling of progressive inter-related and self-sustaining abnormalities may ensue, reversion to states of milder abnormalities is possible if the host is able to restate responses to improve homeostatic equilibrium. With time variation in disease presentation, no single ME/CFS case description, set of diagnostic criteria, or molecular feature is currently representative of all patients at different disease stages. While acknowledging its limitations due to the incomplete research evidence, we suggest the proposed framework may support future research design and health care interventions for people with ME/CFS. | en_US |
dc.description.sponsorship | The UK ME/CFS Biobank was established with a joint grant from the charities ME Association (including continuing support), ME Research UK and Action for ME, as well as private donors. Research reported in this manuscript was supported by the National Institutes of Health under award number 2R01AI103629. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. | en_US |
dc.format.extent | 1 - 13 | - |
dc.format.medium | Electronic | - |
dc.language.iso | en_US | en_US |
dc.publisher | Frontiers Media | en_US |
dc.rights | Copyright © 2020 Nacul, O'Boyle, Palla, Nacul, Mudie, Kingdon, Cliff, Clark, Dockrell and Lacerda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | - |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | - |
dc.subject | myalgic encephalomyelitis/chronic fatigue syndrome | en_US |
dc.subject | chronic fatigue syndrome | en_US |
dc.subject | ME/CFS | en_US |
dc.subject | chronic illness | en_US |
dc.subject | management | en_US |
dc.subject | research | en_US |
dc.title | How Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Progresses: The Natural History of ME/CFS | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.3389/fneur.2020.00826 | - |
dc.relation.isPartOf | Frontiers in Neurology | - |
pubs.publication-status | Published online | - |
pubs.volume | 11 | - |
dc.identifier.eissn | 1664-2295 | - |
dc.rights.holder | Nacul, O'Boyle, Palla, Nacul, Mudie, Kingdon, Cliff, Clark, Dockrell and Lacerda | - |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | 824.22 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License